Development of Triamcinolone Acetonide Loaded Poly(lactide-co-glycolic acid) Dry Powder Inhaler Formulations For The Treatment of Asthma

Abstract

Objective:The objective of this study was to develop triamcinolone acetonide (TAA) loaded poly(lactide-co-glycolic acid) (PLGA) dry powder inhaler (DPI) formulations by using spray dryer and to characterize the formulations with reference to their appropriateness for pulmonary drug delivery.Methods: PLGA dry powder inhalers containing TAA were produced in two stages. In the first step, PLGA microparticles were prepared by emulsion-solvent evaporation method and the DPI formulations were produced by the spray-drying process using mannitol and leucine. TAA loaded PLGA DPI was classified physicochemical properties. The in vitro dissolution test was carried out using modified USP apparatus 2. Aerosol performance was identified with next generation impactor.Results: This study has demonstrated that TAA loaded PLGA DPI were effectively prepared.Scanning electron microscope illustrates the spherical shape, particle size (D50) was established to be between 2.7-3.1 µm and all formulations charged negatively. Special chemical interaction in the DPI was not observed by FT-IR. The in vitro aerosol performance study represented DPI formulations have the proper aerodynamic properties for targeting the lungs.The in vitro TAA release from DPI formulations decreased with increasing of PLGA concentration. Conclusion:Developed PLGA dry powder inhaler formulations containing TAA have shown suitable aerodynamic characteristics to be administered to the lungs thereby could improve in the management of asthma by increasing TAA residency in the lungs for a prolonged period of time.